BRPI0509245A - cloridrato [4-(5-aminoetil-2-flúor-fenil)-piperidina-1-il](4-bromo-3 -metil-5-propóxi-tiofeno-2-il)-metanona como um inibidor de triptase de mastócito - Google Patents
cloridrato [4-(5-aminoetil-2-flúor-fenil)-piperidina-1-il](4-bromo-3 -metil-5-propóxi-tiofeno-2-il)-metanona como um inibidor de triptase de mastócitoInfo
- Publication number
- BRPI0509245A BRPI0509245A BRPI0509245-0A BRPI0509245A BRPI0509245A BR PI0509245 A BRPI0509245 A BR PI0509245A BR PI0509245 A BRPI0509245 A BR PI0509245A BR PI0509245 A BRPI0509245 A BR PI0509245A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- formula
- relates
- present
- aminoethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"CLORIDRATO ¢4-(5-AMINOETIL-2-FLúOR-FENIL)-PIPERIDINA-1-IL!-(4-BROMO- 3-METIL-5-PROPóXI-TIOFENO-2-IL)-METANONA COMO UM INIBIDOR DE TRIPTASE DE MASTóCITO". A presente invenção refere-se ao composto de fórmula 1, ou um pró-fármaco, um sal farmaceuticamente aceitável, ou solvato do dito composto. Ademais, a presente invenção refere-se a uma composição farmacêutica que compreende uma quantidade farmaceuticamente aceitável do composto de fórmula 1, e um veículo farmaceuticamente aceitável. Ademais, a presente invenção refere-se ao uso de um composto de fórmula l como um inibidor de triptase, que compreende introduzir o composto dentro de uma composição que compreende triptase. Ademais, a presente invenção referese ao uso de um composto de fórmula 1 para tratar um paciente que sofre de, ou está submetido a, uma condição fisiológica necessitada de melhora de um inibidor de triptase que compreende administrar ao paciente uma quantidade terapeuticamente eficaz do composto da reivindicação 1. A presente invenção refere-se à preparação de um composto de fórmula 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55692704P | 2004-03-26 | 2004-03-26 | |
PCT/US2005/009899 WO2005097780A1 (en) | 2004-03-26 | 2005-03-24 | [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0509245A true BRPI0509245A (pt) | 2007-09-11 |
Family
ID=34964263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0509245-0A BRPI0509245A (pt) | 2004-03-26 | 2005-03-24 | cloridrato [4-(5-aminoetil-2-flúor-fenil)-piperidina-1-il](4-bromo-3 -metil-5-propóxi-tiofeno-2-il)-metanona como um inibidor de triptase de mastócito |
Country Status (25)
Country | Link |
---|---|
US (1) | US20070142435A1 (pt) |
EP (1) | EP1737848A1 (pt) |
JP (1) | JP2007530580A (pt) |
KR (1) | KR20060130682A (pt) |
CN (1) | CN1956978A (pt) |
AR (1) | AR048336A1 (pt) |
AU (1) | AU2005230934A1 (pt) |
BR (1) | BRPI0509245A (pt) |
CA (1) | CA2560649A1 (pt) |
CR (1) | CR8603A (pt) |
DO (1) | DOP2005000039A (pt) |
EC (1) | ECSP066878A (pt) |
IL (1) | IL178031A0 (pt) |
MA (1) | MA28547B1 (pt) |
MX (1) | MXPA06010610A (pt) |
NO (1) | NO20064811L (pt) |
PA (1) | PA8627601A1 (pt) |
PE (1) | PE20060084A1 (pt) |
RU (1) | RU2330034C1 (pt) |
TN (1) | TNSN06278A1 (pt) |
TW (1) | TW200602035A (pt) |
UA (1) | UA83738C2 (pt) |
UY (1) | UY28821A1 (pt) |
WO (1) | WO2005097780A1 (pt) |
ZA (1) | ZA200607752B (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20071148A1 (es) * | 2006-03-29 | 2007-12-10 | Sanofi Aventis | Mejoras en la preparacion de intermedios que conducen a hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona |
AR065616A1 (es) * | 2007-03-07 | 2009-06-17 | Sanofi Aventis | Sintesis regioselectiva de ullmann de acido 4- bromo-3- metil-5- propoxi- tiofeno-2- carboxilico |
WO2008115912A1 (en) * | 2007-03-21 | 2008-09-25 | Sanofi-Aventis | Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid |
WO2008121669A1 (en) * | 2007-03-29 | 2008-10-09 | Sanofi-Aventis | 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester, its regio-specific synthesis and intermediate thereto |
AR065858A1 (es) * | 2007-03-29 | 2009-07-08 | Sanofi Aventis | Metodo para preparar el inhibidor de triptasa [ 4-(5-aminoetil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona. |
JP2011504499A (ja) * | 2007-11-21 | 2011-02-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | トリプターゼ阻害剤として使用するためのスピロピペリジン |
WO2009094641A2 (en) * | 2008-01-24 | 2009-07-30 | Dor Biopharma, Inc. | Topically active steroids for use in interstitial pulmonary fibrosis |
HUE026331T2 (en) * | 2008-08-22 | 2016-06-28 | Sanofi Sa | [4- (5-Aminomethyl-2-fluoro-phenyl) -piperidin-1-yl] - [7-fluoro-1- (2-methoxy-ethyl) -4-trifluoromethoxy-1H-indol-3-ylmethanone as mast cell tryptase inhibitor |
AR074776A1 (es) | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
FR2955324A1 (fr) * | 2010-01-15 | 2011-07-22 | Sanofi Aventis | [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees |
MY155682A (en) | 2009-09-24 | 2015-11-13 | Sanofi Aventis Us Llc | Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof |
AU2010333892A1 (en) * | 2009-12-23 | 2012-07-19 | Sanofi | Treatment for inflammatory bowel disease |
JP2013515724A (ja) * | 2009-12-23 | 2013-05-09 | サノフイ | ベータ−トリプターゼ阻害剤としてのトロピノンベンジルアミン類 |
SG181504A1 (en) * | 2009-12-23 | 2012-07-30 | Sanofi Sa | Indolyl-piperidinyl benzylamines as beta-tryptase inhibitors |
RU2521357C2 (ru) * | 2010-02-24 | 2014-06-27 | Санофи | Лечение дерматологических аллергических состояний |
DK2763979T3 (en) | 2011-10-07 | 2019-04-01 | Takeda Pharmaceuticals Co | 1-arylcarbonyl-4-oxy-piperidine compounds for the treatment of neurodegenerative diseases |
MX2019009485A (es) * | 2017-02-10 | 2019-11-05 | Genentech Inc | Anticuerpos contra triptasa, composiciones de estos y usos de estos. |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0012362D0 (en) * | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
OA12274A (en) * | 2000-05-22 | 2006-05-09 | Aventis Pharma Inc | Arylmethylamine derivatives for use as tryptase inhibitors. |
-
2005
- 2005-03-21 DO DO2005000039A patent/DOP2005000039A/es unknown
- 2005-03-22 PE PE2005000325A patent/PE20060084A1/es not_active Application Discontinuation
- 2005-03-23 AR ARP050101170A patent/AR048336A1/es not_active Application Discontinuation
- 2005-03-23 UY UY28821A patent/UY28821A1/es unknown
- 2005-03-24 EP EP05731154A patent/EP1737848A1/en not_active Withdrawn
- 2005-03-24 CA CA002560649A patent/CA2560649A1/en not_active Abandoned
- 2005-03-24 WO PCT/US2005/009899 patent/WO2005097780A1/en active Application Filing
- 2005-03-24 AU AU2005230934A patent/AU2005230934A1/en not_active Abandoned
- 2005-03-24 JP JP2007505191A patent/JP2007530580A/ja not_active Abandoned
- 2005-03-24 BR BRPI0509245-0A patent/BRPI0509245A/pt not_active IP Right Cessation
- 2005-03-24 CN CNA2005800164250A patent/CN1956978A/zh active Pending
- 2005-03-24 KR KR1020067019886A patent/KR20060130682A/ko not_active Application Discontinuation
- 2005-03-24 UA UAA200611261A patent/UA83738C2/ru unknown
- 2005-03-24 MX MXPA06010610A patent/MXPA06010610A/es not_active Application Discontinuation
- 2005-03-24 RU RU2006137717/04A patent/RU2330034C1/ru not_active IP Right Cessation
- 2005-03-25 TW TW094109209A patent/TW200602035A/zh unknown
- 2005-03-28 PA PA20058627601A patent/PA8627601A1/es unknown
-
2006
- 2006-09-07 CR CR8603A patent/CR8603A/es not_active Application Discontinuation
- 2006-09-12 IL IL178031A patent/IL178031A0/en unknown
- 2006-09-12 TN TNP2006000278A patent/TNSN06278A1/en unknown
- 2006-09-14 US US11/520,998 patent/US20070142435A1/en active Granted
- 2006-09-15 ZA ZA200607752A patent/ZA200607752B/en unknown
- 2006-09-22 EC EC2006006878A patent/ECSP066878A/es unknown
- 2006-10-20 MA MA29405A patent/MA28547B1/fr unknown
- 2006-10-23 NO NO20064811A patent/NO20064811L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2006137717A (ru) | 2008-05-10 |
ZA200607752B (en) | 2008-05-28 |
CN1956978A (zh) | 2007-05-02 |
UA83738C2 (en) | 2008-08-11 |
WO2005097780A1 (en) | 2005-10-20 |
MXPA06010610A (es) | 2006-12-15 |
EP1737848A1 (en) | 2007-01-03 |
DOP2005000039A (es) | 2005-10-31 |
TNSN06278A1 (en) | 2007-12-03 |
PE20060084A1 (es) | 2006-03-09 |
PA8627601A1 (es) | 2006-01-23 |
IL178031A0 (en) | 2006-12-31 |
ECSP066878A (es) | 2006-11-24 |
NO20064811L (no) | 2006-10-23 |
AU2005230934A1 (en) | 2005-10-20 |
KR20060130682A (ko) | 2006-12-19 |
AR048336A1 (es) | 2006-04-19 |
MA28547B1 (fr) | 2007-04-03 |
RU2330034C1 (ru) | 2008-07-27 |
JP2007530580A (ja) | 2007-11-01 |
CR8603A (es) | 2007-06-08 |
UY28821A1 (es) | 2005-10-31 |
TW200602035A (en) | 2006-01-16 |
US20070142435A1 (en) | 2007-06-21 |
CA2560649A1 (en) | 2005-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0509245A (pt) | cloridrato [4-(5-aminoetil-2-flúor-fenil)-piperidina-1-il](4-bromo-3 -metil-5-propóxi-tiofeno-2-il)-metanona como um inibidor de triptase de mastócito | |
ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
WO2008157537A3 (en) | Compositions and methods of use for treating or preventing lipid related disorders | |
BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
BRPI0606817A2 (pt) | derivados de piridazina e seu uso como agentes terapêuticos | |
BRPI0515500A (pt) | derivados piridazina para inibição de estearoil-coa-desaturase | |
TW200603787A (en) | Topical preparations containing ambroxol | |
TW200700093A (en) | Pharmaceutical composition for the treatment of cancer | |
BRPI0518231A2 (pt) | derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica | |
BRPI0515482A (pt) | derivados heterocìclicos e seus usos como agentes terapêuticos | |
DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
EA200900155A1 (ru) | Модуляторы фармакокинетических свойств лекарственных средств | |
NO20060981L (no) | Pyridazinderivater og deres anvendelse som terapeutiske midler | |
MX2009006613A (es) | Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa. | |
DE602007004618D1 (de) | Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren | |
WO2014018563A2 (en) | Methods for the treatment of cancer | |
BRPI0412343A (pt) | derivados de piridazina e seu uso como agentes terapêuticos | |
EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
BRPI0519124A2 (pt) | composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço | |
ATE514699T1 (de) | Substituierte pyrrolopyrazolderivate als kinaseinhibitoren | |
WO2007046867A3 (en) | Piperidine derivatives and their uses as therapeutic agents | |
AR062068A1 (es) | Sal tartrato de(7)s-7-[(5-fluoro-2-metil-bencil)oxi]-2-[(2r)-2-metilpiperazin-il]-6,7-dihidro-5h-ciclopenta[b]piridina, composiciones farmaceuticas que la contienen, y usos en trastornos asociados fundamentalmente al scn | |
MX2009013501A (es) | Compuestos piperidinicos y sus usos. | |
HK1176318A1 (en) | Injection device | |
NO20085271L (no) | Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: AVENTIS PHARMACEUTICALS, INC. (US) Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |